We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Avrobio Inc
10 own
14 watching
Current Price
$1.18
$0.03
(2.61%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
51.82M
52-Week High
1.93
52-Week Low
0.56
Average Volume
0.51M
Dividend Yield
--
P/E Ratio
--
Market Capitalization51.82M52-Week High1.9352-Week Low0.56Average Volume0.51MDividend Yield--P/E Ratio--What does the Avrobio Inc do?
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company s product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Avrobio Inc make?
News & Events about Avrobio Inc.
Business Wire
2 months ago
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled Orphan Neuro Corporate Panel at Cowens 43rd Annual Health...
Zolmax
1 year ago
AVROBIO, Inc. (NASDAQ:AVRO Get Rating) Investment analysts at Wedbush issued their Q1 2023 earnings per share estimates for AVROBIO in a report issued on Tuesday, May 10th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.29) per share for the quarter. Wedbush...
Business Wire
1 year ago
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the companys common stock to one...
Ticker Report
1 year ago
Wall Street analysts predict that AVROBIO, Inc. (NASDAQ:AVRO Get Rating) will report earnings of ($0.71) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for AVROBIOs earnings, with estimates ranging from ($0.76) ...
Frequently Asked Questions
Frequently Asked Questions
What is Avrobio Inc share price today?
Can Indians buy Avrobio Inc shares?
How can I buy Avrobio Inc shares from India?
Can Fractional shares of Avrobio Inc be purchased?
What are the documents required to start investing in Avrobio Inc stocks?
What is today’s traded volume of Avrobio Inc?
What is today’s market capitalisation of Avrobio Inc?
What is the 52-Week High and Low Range of Avrobio Inc?
What percentage is Avrobio Inc down from its 52-Week High?
What percentage is Avrobio Inc up from its 52-Week Low?
Current Price
$1.18
$0.03
(2.61%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.